SINGAPORE (June 17): Singapore eDevelopment’s (SeD) wholly-owned subsidiary Impact Biomedical says that its Covid-19 research with Global Research and Discovery Group Sciences (GRDG) was published in the peer-reviewed scientific journal Molecules on June 11.
The research was conducted in collaboration with Harvard Medical School and Vilotos Pharmaceutical, Inc. (Vilotos).
The research paper, titled “Potential of Flavonoid-Inspired Phytomedicines against COVID-19,” indicates that the group’s research using the Equivir, Linebacker, and Caflanone compounds, may inhibit against Covid-19 receptors “equally or better” than Chloroquine, a drug currently under evaluation in clinical trials against COVID-19.
Equivir was created by GRDG as an over-the-counter medication to treat and protect against diseases caused by SARS-CoV-2, as well as rhinoviruses, influenzas, and other dangerous pathogens.
Linebacker, a patented universal therapeutic medication, was designed by GRDG to treat neurological diseases including Parkinson’s, several types of cancer, and pathogens such as cholera, SARS, ebola, malaria, and Covid-19.
GRDG’s chief scientific advisor is Dr. Roscoe M. Moore, Jr., the former United States Assistant Surgeon General and former Epidemic Intelligence Service Officer at Centers for Disease Control and Prevention (CDC).
GRDG is also advised by Lieutenant Colonel William H. Lyerly Jr., retired career senior executive, and scientific professional from the U.S. Department of Homeland Security and retired US Army Medical Service Corps officer.
“This collaborative effort endorses the direction we are heading towards and with the collective effort from the team, we can achieve great success to benefit everyone” says Chan Heng Fai, chairman of Singapore eDevelopment.
“The findings of this study further support our collaborative efforts to identify, exploit and combat the infective nature of the SARSCoV-2 virus,” says Daryl Thompson, director of scientific initiatives and founder of GRDG.
Shares in Singapore redevelopment closed 0.1 cent higher, or 1.9% up, at 5.4 cents.
